Register Login

AN2 THERAPEUTICS, INC. (ANTX)

Marks Gilbert Lynn 🟡 adjusted position in 0 shares (6 derivative) of AN2 Therapeutics, Inc. (ANTX) at $17.28 Transaction Date: Mar 19, 2026 | Filing ID: 120230

Full text
Register to leave comments
  • News bot March 23, 2026, 11:14 p.m.

    🔍 Marks Gilbert Lynn (Executive)

    Company: AN2 Therapeutics, Inc. (ANTX)

    Report Date: 2026-03-19

    Transaction Summary:

    • Total transactions: 6
    • Derivative instruments: 6
    • Holdings reported: 0
    • Total shares acquired: 44,769
    • Total shares sold: 44,769

    Detailed Transactions and Holdings:

    • Acquired 10,665 shares of Stock Option (right to buy) at $3.91 per share (Derivative)
      Date: 2026-03-19 | Code: A | Expires: 2031-04-29 | equity_swap_involved: false | shares_owned_after: 10,665.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
    • Sold 10,665 shares of Stock Option (right to buy) at $6.596 per share (Derivative)
      Date: 2026-03-19 | Code: D | Expires: 2031-04-29 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F2
    • Acquired 10,362 shares of Stock Option (right to buy) at $3.91 per share (Derivative)
      Date: 2026-03-19 | Code: A | Expires: 2032-05-11 | equity_swap_involved: false | shares_owned_after: 10,362.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
    • Sold 10,362 shares of Stock Option (right to buy) at $17.28 per share (Derivative)
      Date: 2026-03-19 | Code: D | Expires: 2032-05-11 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F2
    • Acquired 23,742 shares of Stock Option (right to buy) at $3.91 per share (Derivative)
      Date: 2026-03-19 | Code: A | Expires: 2033-06-06 | equity_swap_involved: false | shares_owned_after: 23,742.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
    • Sold 23,742 shares of Stock Option (right to buy) at $5.91 per share (Derivative)
      Date: 2026-03-19 | Code: D | Expires: 2033-06-06 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F2

    Footnotes:

    • F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
    • F2: The option is fully vested.
    • F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

Search

News categories